07:00 , Oct 20, 2016 |  BC Innovations  |  Product R&D

Chaperoning the DJ

  In the latest example of post-dopamine thinking in Parkinson’s disease, Cantabio Pharmaceuticals Inc. has moved upstream of the neurotransmitter with a strategy to block the protein misfolding and oxidative damage that drive neurodegeneration in...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Company News

Cantabio, Purdue University deal

Cantabio and the university’s Purdue Research Foundation partnered to evaluate small molecule chaperone candidates from the biotech that target DJ-1 (PARK7) to treat neurodegenerative diseases, including Parkinson’s disease (PD). Cantabio will have access to resulting...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

Cantabio, University of Antioquia deal

Cantabio and the university’s Neuroscience Research Group will evaluate Cantabio’s small molecule chaperone therapeutic candidates targeting DJ-1 (PARK7) to treat Parkinson’s disease (PD). The partners are focusing on protective effects of Cantabio’s candidates and cellular...
07:00 , Aug 6, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: DJ-1 (PARK7)

Endocrine/metabolic disease INDICATION: Obesity Cell culture and mouse studies suggest inhibiting DJ-1 could help treat obesity. In mice, a high-fat diet increased muscle levels of DJ-1 mRNA compared with a normal diet. In cultured mouse...
07:00 , Sep 27, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Dj-1 (Park7)-deficient mice as models for Parkinson's disease (PD)-associated neurodegeneration Dj-1-deficient mice could be useful models for PD. The Dj-1-deficient animals were generated by backcrossing...
07:00 , Jun 30, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Infectious disease Toxoplasma gondii DJ-1 In vitro studies identified a covalent modifier of the T. gondii DJ-1 protein that could help treat parasite infection....
07:00 , Oct 22, 2009 |  BC Innovations  |  Cover Story

Rat race in PD

The Michael J. Fox Foundation for Parkinson's Research didn't waste any time putting recently published knockout rat technology to work. 1,2 The foundation and Sigma-Aldrich Corp. have partnered to develop models of Parkinson's disease and...
08:00 , Mar 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Parkinson disease (autosomal recessive, juvenile) 2 parkin (PARK2; Parkin); PTEN induced putative kinase 1 (PINK1); DJ-1 (PARK7);...
08:00 , Jan 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer DJ-1 (PARK7); hypoxia-inducible factor 1a (HIF1a) Studies in cell culture suggest that inhibiting DJ-1 signaling may be useful for treating...